-
Mashup Score: 34Lung Cancer Screening Overview | IASLC - 9 day(s) ago
Dr. Hilary Robbins, an epidemiologist with the International Agency for Research on Cancer, and Dr. Brendon Stiles, chief of Thoracic Surgery and Surgical Oncol …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 62National Cancer Institute Renews Georgetown Lombardi Top Designation - Lombardi Comprehensive Cancer Center - 10 day(s) ago
Breaking News:Georgetown’s Cancer Center Awarded Top Designation by Federal Government Designation as Comprehensive Cancer Center Consortium Includes John Theurer Cancer Center The National Cancer Institute (NCI), a part of the National Institutes of Health, has awarded its most prestigious designation — “comprehensive cancer center” status — to Georgetown University‘s Lombardi Comprehensive Cancer Center in recognition […]
Source: lombardi.georgetown.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39
The available approved anti-cancer drugs for Chinese patients are relatively limited because of China’s low participation rate in international clinical trials. Therefore, a focus on approved anti-PD-1/PD-L1 drugs in China is needed. This study aims to assess the heterogeneity of anti-PD-1/PD-L1 antibodies manufactured in China (domestic PD-1/PD-L1) and overseas (imported PD-1/PD-L1) when combined with chemotherapy as the first-line treatment of NSCLC.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57Immunotherapy with radiotherapy for brain metastases in non-small cell lung cancer patients:NEJ060 - 12 day(s) ago
Immune checkpoint inhibitor (ICI)-based treatment has become standard treatment for advanced non-small cell lung cancer (NSCLC) patients. We aimed to reveal the survival benefit of upfront radiotherapy for brain metastases (BMs) in NSCLC patients who received ICI alone (ICI-alone) or with chemotherapy (ICI-chemo).
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24
MedStar Health, D.C. Lung Cancer Conference 2024, 10/19/2024 7:30:00 AM – 10/19/2024 5:00:00 PM, This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past few years, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide an important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques.
Source: medstar.cloud-cme.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Specific genetic alterations, such as MET exon 14 (METex14) skipping, have been identified in NSCLC, allowing targeted therapy. Tepotinib, a highly selective MET inhibitor, has displayed promise in patients with advanced NSCLC. However, challenges arise when identifying treatment strategies for patients with discordant results regarding METex14 skipping detection between diagnostic tests.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 65Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the ITMIG/ESTS Database - 16 day(s) ago
R0 resection and radiation therapy have been associated with improved OS in thymic carcinoma (TC) patients. Here we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 75
PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m2 every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m2 daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS) and objective response rate (ORR). RESULTS Among 461 randomly assigned patients, 229 received liposomal irinotecan and 232 received topotecan. The median follow-up was 18.4 months. The median OS was 7.9 months with liposomal irinotecan versus 8.3 months with topotecan (hazard ratio [HR], 1.11 [95% CI, 0.90 to 1.37]; P = .31). The median PFS per blinded independent central review (BICR) was 4.0 months with liposomal irinotecan a
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2% to 7% of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international guidelines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22024 Texas Lung Cancer Conference Agenda - 25 day(s) ago
2024 Texas Lung Cancer Conference Agenda @TLCconference #TexasLung24
Source: thetlcconference.comCategories: General Medicine News, Hem/OncsTweet
It's been two years since this episode of the @IASLC podcast on lung cancer screening - and we have not made nearly as much progress as we would have hoped. Listen to the science behind #screening with Drs. @hilaryarobbins and @BrendonStilesMD here. https://t.co/8aeO4hjR3z